Vera Therapeutics, Inc.
Vera Therapeutics is a late clinical-stage biotechnology company developing treatments for serious immunological diseases. Its pipeline includes atacicept, a fusion protein that blocks BAFF and APRIL and is being evaluated for IgA nephropathy and other autoimmune kidney diseases; VT-109, a preclinical dual BAFF/APRIL inhibitor; and MAU868, a monoclonal antibody being developed for reactivated BK virus infections, including BK viremia in kidney transplant recipients. Vera’s work centers on developing and commercializing medicines, with worldwide, exclusive development and commercial rights to its three candidates. Atacicept is administered as a weekly subcutaneous injection that patients self-administer at home. The company is also evaluating atacicept in a Phase 2 trial for other autoimmune kidney diseases, including primary membranous nephropathy, focal segmental glomerulosclerosis and minimal change disease. Vera Therapeutics is headquartered in Brisbane, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VERA in the last 30 days.
See all $VERA insider activity →Guggenheim kept its Buy rating on Vera Therapeutics but reduced its price target to $66 from $76, a 13.2% decrease. The new target suggests a 119.0% upside from the Nov 5 close of $30.14.
Raymond James raised its price target on Vera Therapeutics (NASDAQ:VERA) to $87, citing strong early sales of Trutakna, which generated $10.3M in Q3 2026 revenue, exceeding estimates. The company remains unprofitable but is on track for regulatory submissions. Analysts have mixed price targets, ranging from $34 to $100, with a consensus Strong Buy rating.
HC Wainwright & Co. kept Vera Therapeutics at Buy but reduced its price target to $75 from $90, a 16.7% decrease. The new target suggests a 148.8% upside from the Nov 5 close of $30.14.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning VERA (Vera Therapeutics, Inc.). Coverage has skewed bearish: 3 bullish, 3 neutral, and 4 bearish.
Recent VERA coverage spans financial news, earnings and technology.
Analyst target cut suggests reduced upside expectations.
Analyst upgrade and strong launch revenue suggest upside pressure.
Analyst target cut suggests weaker expectations for the stock.
Analyst target cut and modest earnings beat suggest near‑term downside pressure.
Positive clinical data and regulatory filing suggest near-term upside for Vera Therapeutics.
AlphAI scores every news story that mentions VERA with an AI model for sentiment and relevance, and aggregates insider trades from Vera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim kept its Buy rating on Vera Therapeutics but reduced its price target to $66 from $76, a 13.2% decrease. The new target suggests a 119.0% upside from the Nov 5 close of $30.14.
Raymond James raised its price target on Vera Therapeutics (NASDAQ:VERA) to $87, citing strong early sales of Trutakna, which generated $10.3M in Q3 2026 revenue, exceeding estimates. The company remains unprofitable but is on track for regulatory submissions. Analysts have mixed price targets, ranging from $34 to $100, with a consensus Strong Buy rating.
HC Wainwright & Co. kept Vera Therapeutics at Buy but reduced its price target to $75 from $90, a 16.7% decrease. The new target suggests a 148.8% upside from the Nov 5 close of $30.14.
Wedbush reduced Vera Therapeutics' (VERA) price target to $29 from $34, citing competition from Vertex Pharmaceuticals. VERA's Q1 launch generated $10M revenue, but the firm noted cash burn concerns. The stock trades at $30.14, near the new target and InvestingPro's Fair Value of $29.47. Wedbush kept a Neutral rating.
Vera Therapeutics (VERA) reported strong early demand for TRUTAKNA, its newly FDA-approved therapy for IgA nephropathy, with 700 patient start forms since July. The company submitted a supplemental biologics licensing application for full FDA approval, citing final efficacy results from the ORIGIN 3 trial, which showed a 76% reduction in kidney disease progression risk. Vera also plans to submit a marketing authorization application in Europe in Q1 2027.
Vera Therapeutics (VERA) reported Q3 EPS of -$1.30, beating estimates by $0.31, with revenue of $10.2M, surpassing expectations of $3.78M. The stock is down 8.36% over 3 months but up 19.51% year-over-year. Analysts have mixed EPS revisions, and the company's financial health is rated as fair.
Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results • TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Pa
Raymond James reiterated a Strong Buy rating and $84.00 target on Vera Therapeutics (VERA), citing positive kidney disease data. The stock is down 45% YTD but analysts remain bullish. Recent trials showed Trutakna stabilized kidney function in IgA nephropathy patients, with data published in the New England Journal of Medicine.
Cantor Fitzgerald maintained an Overweight rating and $100 price target for Vera Therapeutics (VERA) after positive Phase 3 trial data for Trutakna in IgA nephropathy. The stock rose 4.2% to $29.05. Analysts highlight strong clinical results and financial health, with multiple firms reiterating Buy ratings and varied price targets.
Vera Therapeutics (VERA) reported positive results from its ORIGIN 3 trial of TRUTAKNA for primary IgA nephropathy, meeting all endpoints. The drug showed significant proteinuria reduction and other clinical benefits. Vera plans an FDA filing in Q4 2026. TRUTAKNA received accelerated approval in 2026 and is administered as a weekly autoinjector. The trial enrolled 428 patients, with adverse events reported in 75% of TRUTAKNA patients and 78% of placebo patients.
